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Abstract
Background: Signaling events triggered by interferon (IFN) account for the molecular mechanisms of antiviral
effect. JAK-STAT pathway plays a critical role in IFN signaling, and other pathways are also implicated in IFN-
mediated antiviral effect. Changes in mitogen-activated protein kinase (MAPK) and STAT1 pathways were evaluated
in human hepatoma cells Huh7 and HepG2 upon IFN alpha treatment.
Results: Phosphorylation of ERK was significantly and specifically up-regulated, whereas enhanced phosphorylation
of upstream kinase MEK was unobservable upon IFN alpha treatment. A mild increase in p38 MAPK, SAPK/JNK and
downstream target ATF-2 phosphorylation was detectable after exposure to IFN alpha, indicating differential up-
regulation of the MAPK signaling cascades. Moreover, STAT1 phosphorylation was strongly enhanced by IFN alpha.
Conclusion: IFN alpha up-regulates MAPK and STAT1 pathways in human hepatoma cells, and may provide useful
information for understanding the IFN signaling.
Background
Interferon (IFN), the first cytokine discovered in 1957
[1], has been studied extensively and advances have
been made in biochemical and molecular mechanisms
underlying production and action of IFN system. IFN
family is classified as types I, II, and III, and plays a
pivotal role in innate defense toward virus infection.
Being the first line of defense, type I IFN including IFN
alpha (IFN a) and IFN beta, exert their potent antiviral
activities immediately after virus infection by inhibiting
viral replication and enhancing immune responses [2-4].
Signaling events triggered by IFN are involved in the
molecular mechanisms of the antiviral effects. In parti-
cular, JAK-STAT pathway plays a critical role in the sig-
naling events induced by IFN, and this pathway is
initiated by IFN through interaction with cell surface
specific receptors [5-7]. Upon IFN binding to its recep-
tor, the receptor-associated tyrosine kinases JAK are
phosphorylated and activated, the kinases subsequently
activate transcription factors STAT, and the activated
STAT translocate to nuclear followed by binding to
IFN-stimulated response elements and modulating
transcription of IFN-stimulated genes [8]. The products
of IFN-stimulated genes are known to be responsible for
the antiviral effects of IFN [9]. Apart from the JAK-
STAT pathway, a number of pathways may also be
important for the IFN-dependent biological responses.
Mitogen-activated protein kinase (MAPK) signaling
pathways are composed of three subfamilies including
ERK, SAPK/JNK, and p38 MAPK, and activation of
MAPK pathways contributes to some human diseases
[10]. MAPK pathways are activated by a wide variety of
extracellular signals such as stress, growth factors, and
cytokines. The p38 MAPK or ERK is rapidly phosphory-
lated and activated in response to IFN a treatment
[11,12]. However, involvement of MAPK pathways in
the IFN signaling needs to be fully elucidated.
Hepatitis C virus (HCV) infection is the major cause
of human liver diseases. IFN a is the current approved
treatment for HCV infection [13]. We reported that the
MAPK signaling pathways triggered by HCV envelope
protein E2 were involved in the viral pathogenesis
[14-16]. Since certain signaling events triggered by IFN
a account for its antiviral effect, we wondered whether
the MAPK pathways were also affected and an associa-
tion between MAPK and STAT1 pathways under IFN a
treatment. Difference in cellular response was evaluated
after exposure to IFN a. Human hepatoma cells are
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usually used as models for evaluation of the IFN signal-
ing. Thus, the aim of this study is to reveal regulation of
MAPK and STAT1 signaling pathways by IFN a in
human hepatoma cells Huh7 and HepG2.
Results
1. Influence of IFN a on MEK
Activation of mitogen-activated protein kinases occurs
through phosphorylation of threonine and tyrosine.
Phosphorylation levels of kinases are usually evaluated to
estimate MAPK pathways in response to stimuli [17-19].
To examine whether MEK-ERK pathway would be
affected under IFN treatment, changes in MEK phos-
phorylation were initially analyzed by Western blotting.
Huh7 and HepG2 cells were treated with the increasing
concentrations of IFN a (0, 100, 200, 400, 800 U/ml) for
the indicated time course (15, 30, 60 min) and MEK
phosphorylation was analyzed before and after the treat-
ment. Figure 1A showed that level of MEK phosphoryla-
tion after the IFN a treatment was similar to that before
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Figure 1 Changes in MEK and ERK phosphorylation in response to IFN. Huh7 and HepG2 cells were treated with the indicated
concentrations of IFN a for the indicated time periods. Phosphorylated and total MEK were analyzed in the cells by Western blotting using
antibodies against phospho-MEK or MEK (A). Huh7 cells were treated with the indicated concentrations of IFN a for the indicated time periods.
Phosphorylated and total ERK were analyzed using antibodies against phospho-ERK or ERK (B). Huh7 cells were pretreated with U0126 before
addition of IFN a. Phosphorylated and total ERK were analyzed (C). GAPDH was determined as a control for protein loading. UT, untreated. One
representative experiment out of three is shown.
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such treatment in Huh7 and HepG2 cells. For long time
treatment of IFN, Huh7 cells were cultured in the med-
ium containing the 800 U/ml IFN a for 12, 24, 48, or
72 hrs. Compared with basal level of MEK phosphoryla-
tion without the IFN treatment, there was no increase in
MEK phosphorylation with the IFN treatment for 12 or
24 hrs and the kinase phosphorylation was reduced fol-
lowing the treatment for 48 or 72 hrs (Figure 4). Amount
of total MEK, independent of phosphorylation, was mon-
itored as a control for protein loading. IFN a seems to be
no enhanced effect on MEK phosphorylation.
2. Prevention of IFN a-induced ERK activation by U0126
Next, changes in downstream kinase ERK phosphoryla-
tion were estimated in Huh7 cells treated with the IFN
a. As shown in Figure 1B, phosphorylation of ERK was
increased after exposure to the IFN. Upon the treatment
with IFN a at concentrations ranging from 100 to
800 U/ml, level of ERK phosphorylation was high after
15 min treatment compared to the treatment for
30 min, and a significant increase in ERK phosphoryla-
tion was observed at 60 min. In addition, MEK inhibitor
U0126 was applied to estimate specific regulation of the
kinase cascade by the IFN a. Huh7 was pretreated with
10 μM U0126 prior to the addition of 100 U/ml IFN a.
Figure 1C showed that level of ERK phosphorylation
was markedly decreased in the cells pretreated with the
U0126, indicating that pretreatment with U0126 pre-
vents the IFN a-induced ERK phosphorylation. Con-
stant level of total ERK was also determined. GAPDH
was determined as a control for protein loading. Thus,
IFN a significantly and specifically up-regulates ERK
phosphorylation.
3. Regulation of p38 MAPK, SAPK/JNK, and ATF-2
by IFN a
To evaluate effects of IFN on p38 MAPK and SAPK/
JNK, cell lysates from Huh7 and HepG2 treated with
the different concentrations of IFN a at the indicated
time points were examined by Western blot analysis. In
comparison with phosphorylation of p38 MAPK without
the IFN a treatment, level of p38 MAPK phosphoryla-
tion was slightly increased following the IFN a treat-
ment (Figure 2). As for SAPK/JNK, differential profiles
were observable in response to the IFN a treatment
between HepG2 and Huh7. In HepG2 cells, the IFN a
had no obvious effect on SAPK/JNK phosphorylation.
Whereas SAPK/JNK phosphorylation was enhanced by
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Figure 2 Changes in p38 MAPK, SAPK/JNK, and ATF-2 phosphorylation in response to IFN. Huh7 and HepG2 cells were treated with the
indicated concentrations of IFN a for the indicated time periods. Phosphorylated kinases were analyzed by Western blotting using antibodies
against phospho-SAPK/JNK, phospho-ATF-2, or phospho-p38 MAPK mAb. GAPDH was determined as a control for protein loading. UT, untreated.
Similar results were obtained in four independent experiments, and one representative experiment is shown.
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the IFN a in a time dependent-manner in Huh7 cells,
and the IFN a treatment for 60 min led to a significant
increase in SAPK/JNK phosphorylation. GAPDH was
determined as a control for protein loading.
Transcription factor ATF-2 is a downstream target of
p38 MAPK and SAPK/JNK pathways. SAPK/JNK and
p38 MAPK are known to phosphorylate and activate
ATF-2. Since the upstream kinases p38 MAPK and
SAPK/JNK were activated by the IFN a, changes in
ATF-2 phosphorylation were thereby assessed. Figure 2
showed that the IFN a treatment caused a slight
increase in ATF-2 phosphorylation. Interestingly, treat-
ment of Huh7 with the IFN for 15 min seemed to be
suitable for ATF-2 phosphorylation, which was consis-
tent with the p38 MAPK phosphorylation. Thus, p38
MAPK, SAPK/JNK, and ATF-2 are differentially acti-
vated by IFN a.
4. Regulation of STAT1 by IFN a
Activation of STAT1 is involved in the classical IFN sig-
naling pathways. Huh7 and HepG2 cells were treated
with the increasing concentrations of IFN a for the indi-
cated time course and phosphorylation of STAT1 was
examined in the cells by Western blot analysis. Figure 3
showed that level of STAT1 phosphorylation was
increased in response to the IFN a treatment, and such
phosphorylation was enhanced by the IFN a in a con-
centration dependent-manner, as evidenced that 800 U/
ml IFN a treatment resulted in strong phosphorylation
of STAT1 compared with the treatment of IFN a at the
other concentrations. Moreover, phosphorylation of
STAT1 was also increased upon the IFN a treatment
for a long time period. In Huh7 cells, level of STAT1
phosphorylation was high following the 800 U/ml IFN a
treatment for 12 or 24 hrs compared to the treatment
for 48 or 72 hrs (Figure 4). As a control for protein
loading, blots were probed with antibodies against
STAT1. The data show that IFN a is responsible for the
elevated STAT1 phosphorylation.
Discussion
Being the effective therapy for HCV infection, IFN a has
been focused to reveal the molecular mechanisms under-
lying antiviral effect. Among the multiple mechanisms,
modulation of the signaling events by IFN a is particu-
larly important for the antiviral effect. In this report, we
have investigated regulation of the MAPK and STAT1
signaling pathways by IFN a in human hepatoma cells.
Our data show that the phosphorylation of ERK, p38
MAPK, SAPK/JNK, and ATF-2 is up-regulated by IFN a,
whereas IFN a seems to be no enhanced effect on the
MEK phosphorylation. In response to IFN a treatment,
the STAT1 phosphorylation is also enhanced. The pro-
files of kinetic kinase phosphorylation are shown.
IFN is believed to exert its antiviral effect predomi-
nantly through JAK-STAT signaling pathway. IFN
sequentially phosphorylates and activates JAK kinases
and STAT transcription factors to stimulate the tran-
scription of IFN-stimulated genes. STAT family has
seven known members, and STAT1 and STAT2 play
central roles in induction of the IFN-dependent antiviral
state [9]. Studies show that some viruses have evolved
strategies to evade the host immune responses and set up
successful infections by targeting STAT pathway. Ebola
virus, rotavirus, Venezuelan equine encephalitis virus,
Sindbis virus, and Marburg virus are shown to prevent
the nuclear translocation and phosphorylation of STAT1,
resulting in the impairment of the IFN a-dependent
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Figure 3 Changes in STAT1 phosphorylation in response to IFN. Huh7 and HepG2 cells were treated with the indicated concentrations of
IFN a for the indicated time periods. Western blotting was performed to analyze phosphorylated and total STAT1 using antibody against
phospho-STAT1 or STAT1. UT, untreated. Experiments were performed three times with similar results, and representative results are shown.
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antiviral effect [20-23]. As for HCV, the interference of
HCV proteins with IFN a-induced JAK-STAT pathway
has been proposed to be an escape strategy of HCV [24].
For instance, HCV core protein inhibits IFN a-induced
activation of STAT1 in hepatic cells [25]. IFN a-
mediated STAT activation is blocked in Huh7 cells
containing the HCV genomic replicon [26]. HCV non-
structural protein 5A inhibits IFN a signaling through
suppression of STAT1 phosphorylation in hepatocyte-
derived cells [27]. Consistent with these findings, here we
document that the STAT1 phosphorylation is strongly
enhanced by IFN a in human hepatoma cells. Our data
show that the phosphorylation of STAT1 is enhanced
upon the IFN a treatment not only for a short time per-
iod but also for a long time period. These results are con-
firmed by using the IFN a-2a and 2b.
Changes in the MAPK signaling pathways induced by
the HCV proteins contribute to HCV pathogenesis. In
this regards, it is interesting to examine whether MAPK
pathways are also interfered by IFN a and the associa-
tion between MAPK pathways and JAK-STAT pathway
triggered by IFN a. In the present study, we addressed
the regulation of MEK, ERK, p38 MAPK, SAPK/JNK,
and ATF-2 by the IFN a. The cellular response was
evaluated upon the different concentrations and time
periods of the IFN a treatment. The ERK pathway is
activated by growth factors, cytokines, and virus infec-
tion. Interestingly, we found that the phosphorylation of
ERK was significantly and specifically up-regulated
by the IFN a, whereas enhanced phosphorylation of
upstream kinase MEK was unobservable. The p38
MAPK and SAPK/JNK are the stress-related signal
transduction pathways. The IFN a treatment led to the
mild increase in p38 MAPK and SAPK/JNK phosphory-
lation, and also resulted in the enhancement of down-
stream target ATF-2 phosphorylation. Our data indicate
that IFN a is capable of differentially up-regulating
MAPK pathways in human hepatoma cells. Under the
same condition of IFN a treatment, Huh7 appears to be
susceptible to the IFN a compared with HepG2, imply-
ing that the regulation of MAPK pathways by IFN a
may depend on cell types. In support of our data,
reports show that the p38 MAPK, JNK, and ERK are
activated by IFN gamma or the type I IFN [28-30].
Thus, in addition to classical JAK-STAT pathway,
MAPK pathways are also activated by IFN a and
involved in the IFN signaling. Recent studies illustrate
an important role for the IFN signaling pathways in trig-
gering the host antiviral responses to HCV infection
[31-34]. Our results suggest that the up-regulation of
MAPK and STAT1 pathways by IFN a might be impli-
cated in its antiviral effect, although we have not ruled
out the possible involvement of other pathways in the
signaling events induced by IFN a. Further studies are
still necessary to determine the downstream effects of
these phosphorylation events, including the double-
stranded RNA-activated protein kinase, 2’-5’ oligoadeny-
late synthetase, and Mx.
In conclusion, our results demonstrate that IFN a up-
regulates MAPK and STAT1 signaling pathways in
human hepatoma cells, and provide useful information
for understanding the IFN signaling events.
Methods
1. Materials
Recombinant human IFN a-2a and 2b were obtained
from PBL Interferon Source (Piscataway, NJ) and
Huaxin High Biotechnology (Shanghai, China), respec-
tively. Alkaline phosphatase-conjugated goat anti-rabbit
or anti-mouse IgG were purchased from Vector Lab
(Burlingame, CA). Horseradish peroxidase-conjugated
goat anti-rabbit IgG was from Invitrogen (Camarillo,
CA). Chemiluminescent detection reagents were from
Millipore (Billerica, MA). 5-bromo-4-chloro-3-indolyl






Figure 4 Kinetic changes in MEK and STAT1 phosphorylation after exposure to IFN. Huh7 cells were cultured in the DMEM containing the
IFN a for 12, 24, 48, and 72 hrs, respectively. Western blotting was performed to analyze phosphorylated and total MEK and STAT1. UT,
untreated. One representative experiment out of five is shown.
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phosphate and nitroblue tetrazolium were obtained from
Sigma (St. Louis, MO). MEK inhibitor U0126 and anti-
bodies specific for MEK, ERK, STAT1, phospho-MEK
(Ser217/221), phospho-ERK (Thr202/Tyr204), phospho-
SAPK/JNK (Thr183/Tyr185), phospho-p38 MAPK
(Thr180/Tyr182), phospho-ATF-2 (Thr71), or phospho-
STAT1 (Tyr701) were purchased from Cell Signaling
Technology (Beverly, MA). Dulbecco’s modified Eagle’s
medium (DMEM) and fetal bovine serum were from
HyClone.
2. IFN treatment
Human hepatoma cells Huh7 and HepG2 were grown in
DMEM plus 10% fetal bovine serum, 2 mM L-glutamine,
100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C
with 5% CO2. Cells at 80% confluence were washed twice
with phosphate-buffered saline and then maintained for
24 hrs in serum-free DMEM before treatment with IFN
a-2b. For concentration- and time-dependent stimula-
tion of IFN, cells serum-starved were treated with
increasing concentrations of IFN a-2b dissolved in 0.1%
bovine serum albumin (0, 100, 200, 400, 800 U/ml) for
15, 30, or 60 min. For long time treatment of IFN, Huh7
cells were serum starved for 12 hrs and then cultured in
serum-free DMEM containing 800 U/ml IFN a-2a for 12,
24, 48, and 72 hrs, respectively. Following the above
treatments, cells were washed with phosphate-buffered
saline, collected by centrifugation at 2,000 rpm for 5 min,
lysed in sodium dodecyl sulfate sample buffer on ice, and
heated for 5 min at 100°C. Cell lysates were centrifuged
at 12,000 rpm for 10 min to remove cellular debris,
mixed with sample loading buffer, boiled, and that equal
amounts of protein extracts were subjected to Western
blot analysis.
3. U0126 pretreatment
Huh7 cells serum-starved were pretreated for 1 h with
10 μM U0126 dissolved in dimethylsulfoxide prior to
treatment with 100 U/ml IFN a-2b for another 1 h.
Cells with or without the U0126 pretreatment were har-
vested and lysed for measurement of ERK by Western
blotting.
4. Western blotting
Phosphorylated and total levels of signal molecules were
assayed by Western blotting following the manufac-
turer’s protocol with some modification. In brief, cell
lysates were loaded onto 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. Proteins were sepa-
rated and transferred onto nitrocellulose membranes.
After blocking in 5% nonfat milk for 1 h, membranes
were incubated overnight at 4°C with antibodies against
MEK, ERK, STAT1, phospho-MEK, phospho-ERK,
phospho-SAPK/JNK, phospho-p38 MAPK, phospho-
ATF-2, or phospho-STAT1 at the recommended dilu-
tions, followed by incubation with alkaline phosphatase
or horseradish peroxidase-conjugated secondary antibo-
dies. The blots were developed with 5-bromo-4-chloro-
3-indolyl phosphate and nitroblue tetrazolium substrates
or chemiluminescent detection reagents. Glyceralde-
hyde-3-phosphate dehydrogease (GAPDH) was deter-
mined as a control for protein loading.
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